Impact of amyloid imaging on drug development in Alzheimer's disease
- 4 September 2007
- journal article
- review article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 34 (7), 809-822
- https://doi.org/10.1016/j.nucmedbio.2007.06.015
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosisFEBS Letters, 2005
- Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic MiceNeuron, 2005
- Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in VivoJournal of Biological Chemistry, 2005
- Conformation-dependent antibodies target diseases of protein misfoldingTrends in Biochemical Sciences, 2004
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- FAD Mutations in Presenilin-1 or Amyloid Precursor Protein Decrease the Efficacy of a γ-Secretase Inhibitor: Evidence for Direct Involvement of PS1 in the γ-Secretase Cleavage ComplexNeurobiology of Disease, 2000
- Regulation of APP cleavage by α‐, β‐ and γ‐secretasesFEBS Letters, 2000
- Water-soluble Aβ(N-40, N-42) Oligomers in Normal and Alzheimer Disease BrainsJournal of Biological Chemistry, 1996
- Tau protein and the neurofibrillary pathology of Alzheimer's diseaseTrends in Neurosciences, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991